1. Academic Validation
  2. PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer

PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer

  • Am J Transl Res. 2019 Sep 15;11(9):6055-6065.
Doudou Huang 1 Lin Tang 1 Fang Yang 1 Juan Jin 1 Xiaoxiang Guan 1 2
Affiliations

Affiliations

  • 1 Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing University Nanjing 210002, China.
  • 2 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University Nanjing 210029, China.
PMID: 31632573
Abstract

p110α is an important subunit of phosphatidylinositol-3-kinases (PI3Ks) encoded by PIK3CA. Though PI3Ks are known as crucial regulators of cellular growth and proliferation, the function of PIK3CA mutations in fulvestrant resistance remains elusive. Thus, this study aimed to investigate the roles of PIK3CA mutations in fulvestrant resistance and tumor progression. Using circulating tumor DNA (ctDNA) from four fulvestrant-resistant patients, we found three of them were PIK3CA mutated, one with a novel PIK3CA mutation (p.R115P). In vitro experiments further evaluated the functions of those mutations and underlying mechanisms. We identified PIK3CA mutations could not only confer to fulvestrant resistance, but also promote cell proliferation and migration. Inhibition of corresponding activated pathways could effectively suppress cell growth.

Keywords

Fulvestrant resistance; PIK3CA mutation; estrogen receptor-positive breast cancer.

Figures
Products